Tobias HÃ¶lscher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7177126/publications.pdf

Version: 2024-02-01

53	1,585	279798	315739
papers	citations	23 h-index	38 g-index

62	62	62	2040
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomographyâ€“staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. European Urology Oncology, 2022, 5, 44-51.	5.4	26
2	Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 80-91.	0.8	5
3	Acceptance and efficacy of recommended adjuvant radiotherapy in patients with positive lymph nodes at radical prostatectomy: a preference-based study. World Journal of Urology, 2022, 40, 1463-1468.	2.2	2
4	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). Cancers, 2022, 14, 2073.	3.7	7
5	Ultrahypofractionation of localized prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 89-96.	2.0	22
6	Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics, 2021, 11, 8027-8042.	10.0	39
7	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	10.0	70
8	OLI-P: Toxicity and efficacy of local ablative radiotherapy in PSMA-PET staged, oligometastatic prostate cancerâ€”A phase II trial.. Journal of Clinical Oncology, 2021, 39, 115-115.	1.6	1
9	Dose-intensified versus conventional dose-salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: Six-year outcomes of the SAKK 09/10 randomized phase III trial.. Journal of Clinical Oncology, 2021, 39, 194-194.	1.6	10
10	Radiotherapy in nodal oligorecurrent prostate cancer. Strahlentherapie Und Onkologie, 2021, 197, 575-580.	2.0	11
11	Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2021, 39, 5010-5010.	1.6	3
12	First-In-Human Validation of CT-Based Proton Range Prediction Using Prompt Gamma Imaging in Prostate Cancer Treatments. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1033-1043.	0.8	23
13	Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries. Strahlentherapie Und Onkologie, 2021, 197, 993-1000.	2.0	3
14	Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. European Urology, 2021, 80, 306-315.	1.9	64
15	Intraindividual comparison of [68ÂGa]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Research, 2021, 11, 109.	2.5	32
16	Rapidly Evolving Diffuse Omental Carcinomatosis of Prostate Cancer in 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2021, 46, e216-e217.	1.3	5
17	Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 109-116.	2.0	14
18	Hepatic Vascular Malformation Mimics PSMA-Positive Prostate Cancer Metastasis. Clinical Nuclear Medicine, 2020, 45, e283-e284.	1.3	4

#	Article	IF	Citations
19	Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. Strahlentherapie Und Onkologie, 2020, 196, 589-597.	2.0	10
20	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Research, 2020, 10, 135.	2.5	11
21	Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus ZÃ¶phel, Steffen LÃ¶ck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548â€“51. European Urology, 2019, 76, e103-e104.	1.9	0
22	ï»¿68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. Nuklearmedizin - NuclearMedicine, 2019, 58, 352-362.	0.7	9
23	Dualâ€timeâ€point ⁶⁴<scp>Cuâ€PSMA</scp>â€617â€<scp>PET/CT</scp> in patients suffering from prostate cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 523-532.	1.0	22
24	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. Acta OncolÃ³gica, 2019, 58, 916-925.	1.8	11
25	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. European Urology, 2019, 75, 548-551.	1.9	36
26	Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization. Zeitschrift Fur Medizinische Physik, 2019, 29, 216-228.	1.5	19
27	Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlentherapie Und Onkologie, 2018, 194, 619-626.	2.0	26
28	Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. Radiotherapy and Oncology, 2018, 126, 257-262.	0.6	19
29	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiation Oncology, 2018, 13, 90.	2.7	34
30	Modeling patterns of anatomical deformations in prostate patients undergoing radiation therapy with an endorectal balloon. , 2017, , .		1
31	Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the <scp>SAKK</scp> 09/10 randomized trial on prostate cancer. BJU International, 2017, 120, E45-E51.	2.5	13
32	OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial. Radiotherapy and Oncology, 2017, 123, S58-S59.	0.6	0
33	Hypofractionated radiotherapy for localized prostate cancer. Strahlentherapie Und Onkologie, 2017, 193, 1-12.	2.0	40
34	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology, 2016, 94, e1-e2.	1.0	8
35	Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: First Results of the Randomized Trial SAKK 09/10. Journal of Clinical Oncology, 2015, 33, 4158-4166.	1.6	99
36	Acute toxicity and early quality of life after dose intensified salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: First results of the randomized trial SAKK 09/10.. Journal of Clinical Oncology, 2015, 33, 5038-5038.	1.6	2

#	Article	IF	Citations
37	Treatment of Bone Metastases in Urologic Malignancies. Urologia Internationalis, 2014, 93, 249-256.	1.3	18
38	Use of EORTC Target Definition Guidelines for Dose-Intensified Salvage Radiation Therapy for Recurrent Prostate Cancer: Results of the Quality Assurance Program of the Randomized Trial SAKK 09/10. International Journal of Radiation Oncology Biology Physics, 2013, 87, 534-541.	0.8	23
39	A diseaseâ€specific enteral nutrition formula improves nutritional status and functional performance in patients with head and neck and esophageal cancer undergoing chemoradiotherapy: Results of a randomized, controlled, multicenter trial. Cancer, 2013, 119, 3343-3353.	4.1	66
40	Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. Strahlentherapie Und Onkologie, 2012, 188, 1125-1132.	2.0	1
41	Establishment of a Radiogenomics Consortium. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1295-1296.	0.8	118
42	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPI-II. Radiotherapy and Oncology, 2010, 97, 36-39.	0.6	23
43	Fractionation in prostate cancer â€“ Is it time after all?. Radiotherapy and Oncology, 2010, 96, 1-5.	0.6	24
44	Neoadjuvant Capecitabine Combined with Standard Radiotherapy in Patients with Locally Advanced Rectal Cancer. Strahlentherapie Und Onkologie, 2008, 184, 450-456.	2.0	46
45	Additional PET/CT in week 5â€“6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiotherapy and Oncology, 2008, 88, 335-341.	0.6	74
46	The future of IGRT â€“ Cost Benefit Analysis. Acta OncolÃ³gica, 2008, 47, 1188-1192.	1.8	17
47	PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1322-1323.	6.4	26
48	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. Radiotherapy and Oncology, 2006, 78, 123-130.	0.6	66
49	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiotherapy and Oncology, 2005, 76, 206-212.	0.6	40
50	Effects of radiotherapy on olfactory function. Radiotherapy and Oncology, 2005, 77, 157-163.	0.6	35
51	Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. Radiotherapy and Oncology, 2004, 72, 1-13.	0.6	116
52	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. Radiotherapy and Oncology, 2003, 69, 121-125.	0.6	89
53	Differences in responses to nociceptive stimulation of the oral and aboral oesophagus. Journal of Clinical Neuroscience, 2003, 10, 223-225.	1.5	9